手机验证
4°C
详见说明
Moclobemide
充足
medchemexpress(MCE)
71320-77-9
100mg
生物活性 | Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A[1].Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice. |
|
---|---|---|
IC50 & Target |
|
NMDA (600 µM for 3 days) inhibits the proliferation of PC12 cells.Moclobemide (2 and 10 µM) up-regulates the proliferation in NMDA-treated PC12 cells[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cycle Analysis[2]
Cell Line: | PC12 cell line |
Concentration: | Moclobemide (2 and 10 µM); N-methylaspartate (NMDA) (600 µM) |
Incubation Time: | 3 days |
Result: | Treatment with NMDA significantly reduced the percentage of S-phase, while the percentage of other cell cycle phases did not change notablely.However,the percentage of S-phase increased in the presence of Moclobemide. |
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Chronically stressed male mice (18±2 g) of the Kunming strain[2] |
Dosage: | 40 mg/kg |
Administration: | I.p.; daily |
Result: | BDNF level in the hippocampal subfields including subgranule zone decreased in stressed mice compared with normal control. Chronic treatment with Moclobemide could reverse these changes. |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00534573 | Beersheva Mental Health Center|Tirat Carmel Mental Health Center | Clozapine-induced Hypersalivation | November 2008 | Phase 3 |
NCT01926626 | Jed E. Rose|Philip Morris USA, Inc.|National Institute on Drug Abuse (NIDA)|Duke University | Nicotine Dependence | September 2013 | Phase 2 |
NCT03010761 | China Medical University Hospital | Addiction | January 14, 2016 | Phase 2 |
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL (372.11 mM; Need ultrasonic)
浓度溶剂体积质量 | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.7211 mL | 18.6053 mL | 37.2107 mL |
5 mM | 0.7442 mL | 3.7211 mL | 7.4421 mL |
10 mM | 0.3721 mL | 1.8605 mL | 3.7211 mL |
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
请依序添加每种溶剂: 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (9.30 mM); Clear solution
请依序添加每种溶剂: 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (9.30 mM); Clear solution
请依序添加每种溶剂: 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (9.30 mM); Clear solution
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。